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Abstract: Background: Patients undergoing (chemo) radiotherapy for oropharyngeal squamous cell
carcinoma (OPSCC) are at high risk of malnutrition during and after treatment. Malnutrition can lead
to poor tolerance to treatment, treatment interruptions, poor quality of life (QOL) and potentially
reduced survival rate. Human papillomavirus (HPV) is now known as the major cause of OPSCC.
However, research regarding its effect on nutritional outcomes is limited. The aim of this study was to
examine the relationship between HPV status and nutritional outcomes, including malnutrition and
weight loss during and after patients’ (chemo) radiotherapy treatment for OPSCC. Methods: This
was a longitudinal cohort study comparing the nutritional outcomes of HPV-positive and negative
OPSCC patients undergoing (chemo) radiotherapy. The primary outcome was nutritional status as
measured using the Patient Generated-Subjective Global Assessment (PG-SGA). Secondary outcomes
included loss of weight, depression, QOL and adverse events. Results: Although HPV-positive were
less likely to be malnourished according to PG-SGA at the beginning of treatment, we found that the
difference between malnutrition rates in response to treatment was not significantly different over
the course of radiotherapy and 3 months post treatment. HPV-positive participants had significantly
higher odds of experiencing >10% weight loss at three months post-treatment than HPV-negative
participants (OR = 49.68, 95% CI (2.7, 912.86) p ≤ 0.01). Conclusions: The nutritional status of HPV
positive and negative patients were both negatively affected by treatment and require similarly
intense nutritional intervention. In acute recovery, HPV positive patients may require more intense
intervention. At 3- months post treatment, both groups still showed nutritional symptoms that
require nutritional intervention so ongoing nutritional support is essential.
Keywords: oropharyngeal cancer; OPSCC; head and neck; human papillomavirus; HPV; malnutri-
tion; weight loss; nutrition; PG-SGA
1. Introduction
The prevalence of malnutrition in people with head and neck cancer (HNC) is one
of the highest of all cancers [1,2]. People with oropharyngeal squamous cell carcinoma
(OPSCC) are particularly susceptible as the specific tumor site makes dysphagia and
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odynophagia common [3,4]. In addition, treatment for OPSCC often includes radiotherapy
(RT) combined with chemotherapy. This can result in significant acute toxicity including
mucositis, dysphagia, anorexia, dysgeusia, fatigue leading and longer-term effects such as
radiotherapy induced osteoradionecrosis which can lead to malnutrition, both long and
short term. Malnutrition can lead to poor tolerance to treatment, treatment interruptions,
poor quality of life (QOL), need for feeding tube (FT) insertion, long term gastrostomy
tube dependence and potentially reduced survival rate in people with OPSCC who are
undergoing treatment [1–3,5]. These morbidities worsen with increasing treatment intensity
and with certain types of chemotherapy such as cisplatin which is recommended for OPSCC
treatment [6,7].
The prevalence of OPSCC is increasing in higher socioeconomic countries despite
the relatively stable incidence of other HNC [8]. This is due to the increase in human
papillomavirus (HPV)-associated OPSCC which now accounts for approximately two
thirds of all OPSCC in countries such as Australia [9]. HPV is a sexually transmitted disease
of which 15 types have been associated cancer. HPV 16 and 18 are particularly associated
with mucosal cancers and HPV 16 accounts for up to 90% of all HPV associated HNC [8].
HPV is often diagnosed with histopathology using p16 as a surrogate marker for presence
of HPV though newer evidence recommends bimodal diagnosis with the addition of DNA-
and mRNA-based polymerase chain reaction (PCR) and in situ hybridization (ISH) [10].
People with HPV-positive OPSCC have a better five-year survival rate compared to people
with HPV-negative OPSCC and are often younger and less likely to have a smoking and
drinking history and more likely to have had a greater number of sexual partners [11].
People with HPV-positive OPSCC often present without pre-existing symptoms that affect
nutritional intake such as pain and dysphagia and therefore may be less likely to be
malnourished at commencement of treatment than HPV-negative OPSCC patients [12].
The relationship between HPV-positive status in OPSCC patients and malnutrition are not
well studied.
Patients with HPV-positive OPSCC are known to have better nutritional status at di-
agnosis than people with HPV-negative OPSCC [13–15]. Studies comparing the prevalence
of malnutrition in HPV-positive and negative patients after treatment report similar, if not
worse, nutritional outcomes for people who are HPV-positive compared to those who are
HPV-negative [13,14]. This suggests that people who are HPV-positive are susceptible to
a greater decline in nutritional status and potentially at greater risk of treatment-related
malnutrition than people who are HPV-negative. Some studies attribute the comparatively
worse nutritional outcomes in HPV-positive patients to lack of adherence to nutritional
guidelines which leads to delayed feeding tube insertion and initiation of feeding [13,15].
Other studies suggest that patients with HPV-positive status are at greater risk of a de-
cline in nutritional status due to experiencing worse treatment toxicities [14]. Treatment
de-escalation, defined as a reduction or alteration of chemotherapy and/or radiotherapy
in order to minimize treatment burden in HPV-positive patients, has been proposed with
some promising results in nutritional and swallowing outcomes [16]. However, a recent,
large, randomized, controlled trial (RCT) found that chemotherapy de-escalation resulted
in reduced survival, increased locoregional recurrence and had no advantage in long
term toxicity [7]. As a result, treatment pathways remain the same for HPV-positive and
negative patients.
While research is emerging regarding the impact of HPV status on malnutrition,
there are several gaps including a lack of focus on patients specifically with OPSCC and
inconsistencies in regard to measurement tools and data collection time points. Early
studies often compared HPV-positive and negative patients in a heterogeneous HNC
population but we now know that the causal link between HPV and survival is unique to
OPSCC [17]. Recent research regarding the prevalence of malnutrition is scarce and has
only included percentage weight loss or categorical reference ranges which vary (e.g., ≥5%
or ≥10% weight loss) instead of a more comprehensive and validated tool to diagnose
malnutrition [13,14]. It is now well accepted that weight loss alone is insufficient to
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diagnose malnutrition in cancer patients and, as a result, more specific diagnostic tools
have been validated in this population [18,19]. Finally, most HPV comparison studies
do not take into account the differences in baseline malnutrition between HPV positive
and negative patients, confounding the inferences that can be made about the differential
effects of radiotherapy on HPV-positive patients. There is also a lack of research examining
nutritional outcomes post treatment and at multiple time points. This is important as poor
nutritional status can continue far past cessation of treatment [20–22]. Factors such as
depression and poor QOL are also known to effect nutritional outcomes in the wider HNC
population [23,24] but their relationship with HPV status and nutritional outcomes has not
been well studied. Therefore, these factors were assessed in our study.
Despite the better prognosis associated with HPV-positive OPSCC, treatment remains
the same and the risk of poor nutritional outcomes is high. A better understanding of
nutritional outcomes in relation to HPV status could help to inform targeted nutritional
interventions and therefore contribute to better nutritional and treatment outcomes for
people who are undergoing treatment for HPV-positive OPSCC. The aim of this study
was to examine the relationship between HPV status and nutritional outcomes, including
malnutrition and weight loss during and after patients’ (chemo) radiotherapy treatment
for OPSCC. Based on previous research, we hypothesized that patients with HPV-positive
status would experience more malnutrition (primary outcome), more weight loss, more
depression, lower QOL and more adverse events (secondary outcomes) during and after
treatment compared to patients with HPV-negative status.
2. Materials and Methods
2.1. Study Design
This longitudinal, cohort study was a sub-study of a stepped wedge, cluster, ran-
domized controlled trial titled, ‘Eating As Treatment (EAT)’. Detailed information on the
original study protocol is published elsewhere [25]. Data collected during EAT from two
sites, Peter MacCallum Cancer Centre, Melbourne and Princess Alexandra Hospital, Bris-
bane were used for this sub-study, as p16 status is routinely collected at these sites as a
marker of HPV status.
2.2. Participants
Eligible participants were selected from the two participating sites. Informed, written
consent was provided in the original trial for data to be used for related studies. EAT was
approved by Hunter New England Health (HREC/12/HNE/108).
All outcome assessments were conducted by an independent researcher at four time
points: first week of radiotherapy (RT), last week of RT, one-month post-RT and three-
months post-RT. All baseline characteristics and covariates such as tumor stage and treat-
ment type were collected by a research assistant via chart review with the exception of
p16 status which was retrospectively collected from confirmed histopathology reports.
2.3. Inclusion Criteria
Eligible patients were aged 18 years or older who had pathologically confirmed
diagnosis of OPSCC. Immunohistochemistry (IHC) staining using Roche CINtec histology
kit, clone E6H4was used to confirm p16 status. They were planned for definitive or
postoperative radiotherapy with curative intent (chemoradiation permitted including
neoadjuvant and adjuvant chemotherapy), the prescribed radiation dose being at least
60 gray as regional nodal irradiation. They were available for follow-up for at least 6 months
post study initiation and provided written, informed consent. Patients were excluded if
they were unable to communicate in English; had organic brain disease (impairing ability to
complete questionnaires), had T1 or T2 glottic carcinoma undergoing small fields radiation
therapy or T1 and T2 tonsil cancer undergoing unilateral treatment.
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2.4. Primary Outcome
The primary outcome of nutritional status was measured using the Patient Generated
-Subjective Global Assessment (PG-SGA) [26]. The PG-SGA is reliable and validated in
an oncology population and in Australia, is the recommended assessment tool for mal-
nutrition in the oncology population [18,27]. It produces a score between 1–49 (where
1 requires no intervention, 2–3 requires low intensity intervention, 4–8 indicates dietetic in-
tervention dependent on symptoms and ≥9 indicates critical need for dietetic intervention)
and a categorical global assessment (A-indicating well nourished, B-indicating moderately
malnourished or C-indicating severely malnourished). The score incorporates prognostic
factors of nutritional status such as weight change, dietary intake, factors affecting nu-
tritional intake, metabolic stress, subcutaneous fat and muscle wastage and presence of
disease.
2.5. Secondary Outcomes
Secondary outcome measures included loss of weight (LOW), depression, QOL and
adverse events including treatment interruptions, unplanned hospital admissions and
length of stay (LOS) of these admissions, reactive nasogastric tube (NGT) insertions for
feeding, dietary adequacy, nutrition impact symptoms (NIS) and mortality at two years
post-treatment.
2.6. Loss of Weight
The weight (kg) of participants was recorded using electronic standing scales, at all-
time points. Percentage LOW from baseline was calculated at each time point. LOW was
also categorized into >5% LOW and >10% LOW as these are cut off points used in other
literature for important weight loss and used clinically to indicate significant weight loss.
2.7. Depression
Depression was assessed using the validated Patient Health Questionnaire 9 (PHQ-9) [28].
This is a self -administered tool to measure the severity of 9 diagnostic criteria for depres-
sion. It provides a score of depression severity 0–27 (27 as the highest severity) with a score
of ≥14 indicating the presence of major depressive disorder.
2.8. Quality of Life
QOL was assessed using the European Organization for Research and Treatment of
Cancer, Core Quality of Life Questionnaire (EORTC QLQ-C30). This is a 30-item self-report
questionnaire designed and validated to measure QOL in patients with cancer [29]. It
includes 5 functional scales (physical, role, cognitive, emotional and social), 3 symptom
scales (fatigue, pain, nausea and vomiting), a global health status scales and 6 single items
assessing the financial impact of disease and commonly reported symptoms (dyspnea, loss
of appetite, insomnia, constipation and diarrhea).
2.9. Dietary Adequacy, NIS and Reactive NGT Insertions
Dietary adequacy was obtained from a section (Box 2) of the PG-SGA. Scores for Box
2 are measured on a scale of 0–5 (0 indicating normal nutritional intake and 5 indicating
eating very little of anything). NIS were obtained from Box 3 of the PG-SGA. Scores for
Box 3 are measured on a scale of 0–24 (0 indicating the patient has no symptoms that are
affecting intake and 24 indicating that intake is severely impacted by symptoms). Reactive
NGT insertions were measured as the proportion of patients with NGT inserted after the
start of treatment in relation to poor oral intake.
2.10. Adverse Events
Treatment interruptions were measured as total number of participants with un-
planned interruptions to their radiotherapy schedule. Unplanned hospital admissions
were measured as total number of admissions from start of radiotherapy to 3 months post
Nutrients 2021, 13, 514 5 of 13
treatment and LOS was calculated as a total of all participants’ hospital stays for each
HPV status group. Mortality was measured as proportion of participants who had died by
two-years post treatment.
2.11. Sample Size
This exploratory study used an opportunistic sample of patients with OPSCC who
participated in a large multi-center trial, examining the entirety of OPSCC patients from
two of the sites.
All analyses were conducted using STATA 13 [30]. The primary outcome, PG-SGA
score, was analyzed using a Linear Mixed Models (LMM) regression. The assumptions of
LMM were assessed by inspecting appropriate residual plots. The model used an unstruc-
tured covariance examining differences between HPV-positive and negative patients and
controlled for the effects of the EAT trial intervention, differences between hospitals, time
of assessment (start of RT, end of RT, 1-month post-RT, 3-months RT), calendar date, tumor
site, tumor stage and baseline nutritional status. The model included a random individ-
ual level intercept to account for the repeated measures on individuals over assessment
time-points.
Secondary outcomes were assessed using the same model to analyze the differences
across all time points. Percentage LOW, depression (PHQ-9) and QOL (QLQ C30) were
analyzed using LMM while the categorical variables such as the PG-SGA, >5 and >10%
weight loss were analyzed using logistic mixed effects models.
Treatment interruption was analyzed using a logistic regression. Unplanned hospital
admissions were analyzed using a negative binomial regression. Both models included
HPV status, intervention group, baseline nutritional status, hospital and calendar time.
3. Results
3.1. Participants
Data was available from 83 participants (70 HPV-positive and 13 HPV-negative) from
the two sites between July 2013 and January 2016. There was one dropout from each of
the p16 positive and negative groups (n = 2). Both of these were lost to follow-up post-
treatment, the reasons stated were; living in rural areas and not able to return to hospital
for follow up assessments. None of the participants died during the course of the study.
Patient characteristics at baseline can be seen in Table 1.
Table 1. Patient characteristics at baseline.
Variable
HPV-Negative HPV-Positive
n = 13 (16%) n = 70 (84%)
Categorical variables, n (%)
Male 12 (92) 61 (87)
Aboriginal or Torres Strait Islander 0 2 (3)
Non-English speaker at home 1 (8) 1 (1)
Marital status
Married/Defacto 9 (69) 44 (63)
Separated/Divorced/Widowed 2 (15) 17 (24)
Single/Never married 2 (15) 9 (13)
Highest level of education
Primary school 6 (46) 6 (9)
High school 3 (23) 23 (33)
University/Vocational
college 4 (31) 41 (59)
Tumor stage (AJCC 7)
I 0 2 (3)
II 2 (15) 10 (14)
III 0 14 (20)
IV 11 (85) 44 (63)




n = 13 (16%) n = 70 (84%)
Concurrent chemotherapy 13 (100) 61 (87)
Post-operative radiotherapy 0 (0) 9 (13)
Prophylactic PEG 4 (31) 22 (31)
Prophylactic NGT 2 (15) 2 (3)
Received EAT intervention 7 (54) 42 (60)
Substance use
Harmful Alcohol Use and Likely Dependence
(AUDIT ≥8) 5 (38) 18 (26)
Reported current smoking 3 (23) 8 (11)
Nicotine Dependence (AUDIT ≥8) 6 (46) 3 (4)
Continuous variables, mean (s.d)
Age in years 56 (9.4) 57 (7.4)
Prescribed radiation (Gy) 69 (2.8) 69 (8.3)
Depression (PHQ-9) 4.1 (4.1) 3.4 (3.7)
Baseline Nutrition Variables
PG-SGA score mean (s.d) 8.1 (6.9) 4.1 (3.9) *
PG-SGA category (B/C) n (%) # 6 (46) 8 (12) *
BMI in Kg/m2 mean (s.d) 24.5 (5.3) 29.7 (6.2) *
Abbreviations; AJCC 7 = American Joint Committee on Cancer, Version 7; AUDIT ≥ 8 = Alcohol Use Dis-
orders Identification Test; BMI = Body Mass Index; EAT = Eating As Treatment; Gy = gray; HPV = Human
papillomavirus; NGT = Nasogastric Tube; PEG = Percutaneous Endoscopic Gastrostomy; PG-SGA = Patient
Generated-Subjective Global Assessment; PHQ-9 = Patient Health Questionnaire 9; s.d = standard deviation.
* Significant difference between groups (p < 0.01). # Category A = Well Nourished; B = Moderately malnourished;
C = Severely malnourished.
3.2. Primary Outcome
Malnutrition
Mixed models controlling for variables such as baseline nutritional status and the
effect of the larger trial intervention (see statistical methods above), found no significant
difference in PG-SGA category and scores between HPV-positive and negative patients
over the course of treatment and recovery (Table 2 and Figure 1).
Table 2. Primary outcome: HPV-positive and HPV-negative in a linear mixed model of mean PG-SGA score and category
across end of treatment, 1 months and 3 months post treatment.
Variable HPV-Negativen = 13
HPV-Positive
n = 70 Statistic p-Value 95% CI
PG-SGA score, mean (s.d) * β = 0.80 0.44 −1.22, 2.82
Last wk treatment 15.3 (7.5) 13.8 (4.9)
1-mth post-treatment 10.3 (5.2) 10.8 (5.5)
3-mth post-treatment 6.3 (6.2) 7.5 (4.7)
PG-SGA category B/C, n (%) # OR = 0.50 0.30 0.14, 1.83
Last wk treatment 11 (85) 62 (89)
1-mth post-treatment 8 (62) 50 (71)
3-mth post-treatment 5 (38) 30 (43)
Abbreviations; HPV = Human papillomavirus; CI = confidence interval; OR = odds ratio; PG-SGA = Patient Generated-Subjective
Global Assessment; s.d = standard deviation. * Higher score indicates worse nutritional status or risk. # Category A = Well Nourished;
B = Moderately malnourished; C = Severely malnourished.
3.3. Secondary Outcomes
3.3.1. Loss of Weight
HPV positive participants had significantly higher odds of experiencing >10% weight
loss at three-months post-treatment than HPV negative participants (OR = 49.68, 95%CI
(2.7, 912.86) p ≤ 0.01) (Table 3). The average difference between groups across all time
points was not significant.
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Figure 1. Mean PG-SGA (Patient Generated-Subjective Global Assessment) score by HPV (Human papillomavirus) status
over all timepoints with 95% Confidence intervals.
3.3.2. Depression
Across all time points, there were no statistically significant differences in depression
scores between HPV-positive and HPV-negative patients (Table 3).
3.3.3. Adverse Events
HPV-positive patients had statistically significant higher odds of unplanned admis-
sions than HPV-negative patients (OR = 3.00, 95% CI (1.12, 8.02), p = 0.03) (Table 3). Mortal-
ity at 2 years post treatment was 1.5 times greater for HPV-positive patients compared to
HPV-negative patients (30% versus 7%, p < 0.01).
3.3.4. Reactive NGT Insertions, Dietary Adequacy and Nutrition Impact Symptoms
There was no statistically significant difference in reactive NGT insertions, dietary
adequacy and NIS between groups (Table 3).
3.3.5. Quality of Life
There was no statistically significant difference in global QOL scores, symptom and
functional scale scores between groups across all time points (Table 4). The exception is
cognitive decline which was worse for HPV positive patients (p < 0.01).
Nutrients 2021, 13, 514 8 of 13
Table 3. Secondary outcomes: HPV-positive and HPV-negative in a linear mixed model of mean LOW, depression, PG-SGA
Box 2 and 3 across end of treatment, 1 months and 3 months post treatment.
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Depression, mean (s.d)   β = 0.49 0.66 −1.72, 2.70 
 First wk treatment 4.2 (4.1) 3.4 (3.7)    
 Last wk treatment 7.1 (3.2) 9.9 (5.5)    
 1-mth post-treatment 6.3 (5.1) 6.3 (4.9)    
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PG-SGA Box 3 mean (s.d)   β = 0.53 0.41 −0.74, 1.79 
First wk treatment 2.6 (2.8) 1.1 (2.2)    
Last wk treatment 4.8 (4.0) 4.7 (3.9)    
1-mth post-treatment 2.8 (4.0) 3.4 (3.7)    
3-mth post-treatment 1.9 (2.9) 2.3 (2.9)    
Unplanned admissions, n  6 64 OR = 3.00 0.03 1.13, 8.02 
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Reactive NGT, n (%) 3 (23) 21 (30) OR = 0.75 0.65 0.22, 0.26 
Mortality at 2-yrs n (%) 4(31) 5(7) β = −1.58 <0.01 −2.27, −0.89 
Abbreviations: HPV = Human papillomavirus; CI = confidence interval; IRR = Incidence Rate Ratio; LOS = length of stay; 
LOW = loss of weight; NGT = Nasogastric Tube; OR = odds ratio; PG-SGA = Patient-Generated Subjective Global Assess-
ment; RT = radiotherapy; s.d = standard deviation. 
3.3.2. Depression 
Across all time points, there were no statistically significant differences in depression 
scores between HPV-positive and HPV-negative patients (Table 3). 
3.3.3. Adverse Events 
HPV-positive patients had statistically significant higher odds of unplanned admis-
sions than HPV-negative patients (OR = 3.00, 95% CI (1.12, 8.02), p = 0.03) (Table 3). Mor-
tality at 2 years post treatment was 1.5 times greater for HPV-positive patients compared 
to HPV-negative patients (30% versus 7%, p < 0.01). 
  
bbreviations: HPV = Human papillomavirus; CI = confidence interval; IRR = Incidence Rate Ratio; LOS = length of stay; LOW = loss
of weight; NGT = Nasogastric Tube; OR = odds ratio PG-SGA = Patient-Generated Subjective Global Assessment; RT = radiotherapy;
s.d = standard deviation.
Table 4. HPV-positive and HPV-negative in a linear mixed model of mean Health Related Quality of
Life (QLQ C30) across end of treatment, 1 months and 3 months post treatment.
Variable β Statistic p-Value 95% CI
Total HRQOL score * 2.63 0.50 0.26, 0.68
Global Health * 2.83 0.53 −6.17, 11.83
Functional Outcomes *
Role functioning −2.61 0.70 16.23, 10 99
Physical Functioning 2.91 0.54 −6.54, 12.37
Emotional Functioning 0.47 0.91 −7.50, 8.43
Cognitive Functioning −14.34 <0.01 −75, −5.04
Social Functioning −3.03 0.58 −13.81, 7.77
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Table 4. Cont.
Variable β Statistic p-Value 95% CI
Symptom Scales #
Fatigue −3.44 0.53 −14.06, 7.18
Nausea & Vomiting −5.69 0.33 −17.94, 6.56
Pain 9.59 0.11 −2.26, 21.44
Dyspnea −5.69 0.21 −14.57, 3.20
Insomnia 0.82 0.89 −11.27, 12.91
Appetite Loss −10.91 0.19 −27.33, 5.50
Constipation 4.28 0.47 −7.42, 15.99
Diarrhea −2.99 0.48 −11.29, 5.29
Financial difficulties 2.48 0.75 −12.73, 17.69
Abbreviations: HPV = Human papillomavirus; CI = confidence interval; HRQOL = Health-Related Quality of
Life Questionnaire (QLQ-C30). * Higher score is better. # Lower score is better.
4. Discussion
This is the first longitudinal study, to our knowledge, in which the impact of HPV
status on malnutrition and related factors has been investigated at various time points
during and after RT treatment using a diagnostic tool validated in the oncology population.
The detrimental effects of treatment in the heterogenous HNC population has been widely
studied and, as a result, nutritional guidelines have been established [27]. These guidelines
are based on the wider HNC population and are not specific to the HPV-positive patients
who now account for the majority of OPSCC patients and where malnutrition at diagnosis
is less prevalent. We found that treatment has a similarly detrimental effect on nutritional
outcomes for HPV-positive as negative OPSCC patients and therefore these patients require
equivocal if not more intense nutritional intervention.
In contrast to previous studies [13,14], we did not find worse nutritional outcomes
for the HPV-positive group at cessation of treatment. These unexpected results were
likely partly due to the relative worse nutritional outcomes for HPV-negative patients
in our study compared to HPV-negative patients included in previous research. The
difference in nutritional outcomes between studies could also be explained by differences
in measurement of malnutrition, as these previous studies used weight loss alone as
a marker of nutritional status whereas the more comprehensive PG-SGA was used in
this current study. Weight loss alone could potentially underestimate malnutrition for
HPV-negative patients.
The PG-SGA is the recommended tool for malnutrition assessment in radiotherapy pa-
tients in Australia [27]. It has shown to have high specificity and reliability in the oncology
population [18]. This tool was utilized as it includes a description of symptoms commonly
affecting the nutritional status of oncology patients, which can then be addressed by nutri-
tional intervention. Other single measure tools such as biochemical and anthropometrical
markers have inherent difficulties with interpretation and measurement and do not allow
for the underlying symptoms to be identified and addressed.
Differences in treatment modality may be an additional explanation for the difference
between the results of our study and previous studies. Concurrent chemotherapy admin-
istration and intensity of RT are known to worsen nutritional outcomes [31,32]. While in
our study HPV-positive and negative patients had similar rates of adjuvant chemotherapy
and RT doses, HPV-negative patients in previous studies had less intense treatment [13,14].
This could increase the difference between HPV-positive and negative patients in previous
work. It is also acknowledged that in our study, while the number of ≥3 stage disease
included in the study is similar, there were more Stage 4 OPSCC patients who could have
greater nutritional symptoms in the HPV negative group. This could decrease the differ-
ence between groups in our study given the potential for worse nutrition related symptoms
with higher stage disease.
We did find evidence of more severe weight loss at 3 months post treatment in HPV-
positive OPSCC patients suggesting a slower recovery for these patients. This more severe
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weight loss was unlikely due to worse toxicities as patient-reported symptoms were similar
for HPV-positive and negative patients overall and unplanned admissions, an indirect
measure of treatment toxicity, were predominately seen during treatment. HPV-positive
patients did have significantly higher BMI at the beginning and end of treatment which
may have lessened both patients’ and clinicians’ concern regarding weight loss and reduced
likelihood of adherence to nutritional guidelines. Future research is needed to confirm this
potential slower recovery post treatment in HPV-positive patients and the reasons for this
so that the appropriateness of current recommendations for nutritional and supportive care
post-treatment for HPV-positive patients can be investigated. This is especially important
given that the frequency of follow up recommended for HNC patients is based on patients
undergoing radiotherapy alone and current best practice treatment for this patient group
has the added detrimental impact on nutrition associated with chemotherapy treatment [27].
Given the known increased 5-year survival rate for these patients, longer term research
beyond 3 months post treatment is also warranted.
Previous studies [13,15] suggest lack of adherence to guidelines in relation to insertion
and timing of insertion of feeding tubes (FT) in the HPV-positive population contributes
to poorer nutritional outcomes. Therefore, closer adherence to these guidelines for both
HPV-positive and negative OPSCC in our study may help to explain the similar nutritional
outcomes. FT insertion is generally recommended at 5% LOW for HNC patients undergo-
ing treatment [33]. In our study, 87% of HPV-positive patients and 83% of HPV-negative
patients had >5% LOW and 64% and 69% respectively had a feeding tube inserted. Van-
gelov et al. found slightly more FT insertions for HPV-positive than HPV-negative patients
(64% vs. 60%). However, as ≥5% LOW was seen in 94% of HPV-positive patients and
60% of HPV-negative patients, the proportion of patients potentially requiring FTs and
not receiving them is higher in the HPV-positive group compared to HPV-negative group.
In our study, prophylactic feeding was slightly lower for HPV-positive patients (34%)
compared to HPV-negative OPSCC patients (46%) while rates of reactive NGT insertion
was no different. Vangelov et al. [11] found greater differences in prophylactic feeding
rates between the two groups (24% for HPV-positive vs. 50% for HPV-negative) poten-
tially leading to greater weight loss in the HPV-positive group. Current guidelines [27]
recommend that prophylactic FT insertion be considered in HNC patients undergoing
treatment. Predictors of patients who are most likely to require them are well studied and
include poor nutritional status at presentation [22,34,35]. Results of our study show that
favorable nutritional status at presentation does not prevent decline in the nutritional status
of HPV-positive patients and so may not be useful in determining appropriateness for
prophylactic feeding in this population. Predictive factors for HPV status and prophylactic
FT insertion in HPV positive patients could be the subject of future research.
The significant difference in unplanned admissions is interesting. It may be an indirect
marker for clinician-reported treatment toxicity given patients are usually admitted for
management of side effects. This is supported by previous evidence that clinician-reported
toxicities are worse for HPV-positive patients though this same study reported no dif-
ference in unplanned admissions [14]. Given we found no difference in patient reported
toxicities, our results support these previous findings that treatment toxicity and unplanned
admissions are not correlated in the HPV population [14]. The lack of RT interruptions
seen in HPV-positive patients, albeit only a trend compared to HPV-negative patients, may
have contributed to unplanned admissions indirectly as the quest to avoid interruptions
can lead to admission for symptom management. Some research suggests patients who
start treatment with less pre-existing symptoms predict better future QOL outcomes and
this, in turn, relates to worse patient-reported outcomes in recovery [36,37]. Therefore,
HPV-positive patients may be more likely to perceive functional outcomes as severe during
and after treatment and therefore seek admission. Psychological interventions may be
useful to address patients’ perceptions and adherence to nutritional guidelines. Successful
interventions have been studied in the wider HNC population and have been shown to
improve adherence to nutritional guidelines, nutritional outcomes and QOL [25,38]. There
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are currently no known psychological interventions in the HPV-positive population and
more research in this population may be warranted.
The higher proportion of HPV-positive patients than HPV-negative patients in the
OPSCC population is a limitation of this and earlier studies. The difference in sample
size between groups could explain the lack of statistical significance found. This study
was a post-hoc sub-study of a previous work which meant the sample is limited and a
prospective sample size calculation was not conducted. The sample, while not small, was
not balanced (n = 70 vs. n = 13). The study had 90% power to find a large effect (Cohen’s
d = 0.8), 53% power to find a medium effect (d = 0.5) and only 12% power to find a small
effect (d = 0.2). As such, non-significant findings should be viewed in the context of this
sample not being powered to find smaller effect sizes and the subsequent higher risk of
Type 2 error. Further research should address this limitation.
The current study was conducted in tertiary treatment centers with well-established
multidisciplinary teams, so findings may not be generalizable to smaller treatment centers.
There may have been individual differences in nutritional intervention as nutritional
interventions were undertaken by different clinicians. As mentioned in the introduction,
bimodal detection of HPV status is now recommended and this was not available in this
study which could potentially overestimate positive HPV cases.
5. Conclusions
In this first study of longitudinal change of nutritional status in relation to HPV status
in OPSCC using validated measures, two main outcomes are seen. Firstly, we found the
impact of treatment on HPV-positive patients’ nutritional status, whose baseline nutrition
was superior, was not significantly different by the final week of RT treatment to that
of HPV-negative patients and this continued into the post-treatment period. Secondly,
HPV-positive patients had significantly greater patients with >10% LOW at 3 months
post treatment and significantly more unplanned admissions. We found similar rates of
malnutrition were associated with similar % weight loss, depression scores, QOL and
reactive NGT rates. Our results differ to other studies in that HPV-positive patients did not
have worse nutritional outcomes by the end of treatment. This is likely due to difference
in research methodology and potentially due to better adherence to guidelines for HPV-
positive patients in our study. Nevertheless, the nutritional status of HPV positive and
negative patients were both negatively affected by treatment and require similarly intense
nutritional intervention during treatment. In acute recovery, HPV positive patients may
require more intense intervention. At 3-months post treatment, both groups still showed
nutritional symptoms that require nutritional intervention so ongoing nutritional support
is essential. Further prospective research with a larger sample size is needed to confirm the
results found in this study and could include sociological and psychological exploration
with a focus on interventions to improve adherence to nutritional guidelines and support
to help manage patient expectations. The superior survival outcomes for HPV-positive
patients mean these patients are living longer so a study of long-term effects of treatment on
nutritional status and contributing factors along with appropriate nutritional intervention
is warranted.
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